Routine follow-up of patients with established WHO Group 1 PAH.
Monitoring treatment response without invasive hemodynamics (RHC).
Risk assessment at quarterly or bi-annual intervals.
When to Use
REVEAL Lite 2 is intended for follow-up assessments. Baseline risk stratification should ideally use the full 13-variable REVEAL 2.0 score incorporating Right Heart Catheterization.
REVEAL Lite 2 has a C-statistic of 0.70. While slightly lower than the full 2.0 version (0.76), it provides reliable risk categorization purely through bedside assessment and standard labs.
Section 4
Evidence Appraisal
Primary Source
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2.
